Main public logs

Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

• 10:56, 12 February 2025 Nehal Eid talk contribs created page Zenocutuzumab-zbco (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |drugClass=HER2-and HER3-directed antibody |indicationType=treatment |indication=It is a bispecific HER2-and HER3-directed antibody indicated for the treatment of: • Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.* • Adults with advanced, unresectable or metastatic pancreatic adenocarc...")
• 10:20, 12 February 2025 Nehal Eid talk contribs created page Cosibelimab-ipdl (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=programmed death ligand-1 (PD-L1) blocking antibody |indicationType=treatment |indication=It is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. |adverseReactions=The most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea,...")
• 09:56, 12 February 2025 Nehal Eid talk contribs created page Ensartinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=Kinase inhibitor |indicationType=treatment |indication=It is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. |adverseReactions=Most common adverse reactions (incidence≥20%) were rash, musculoskeletal pain, constipation, pruritus, cough, nause...")
• 19:03, 31 January 2025 Nehal Eid talk contribs created page Olezarsen (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=an |drugClass=Oligonucleotide |indicationType=treatment |indication=It is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). |adverseReactions=1-Injection site reactions 2-Decreased platelet count 3-Arthralgia |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>''...")
• 17:10, 30 January 2025 Nehal Eid talk contribs created page Concizumab (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Concizumab in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported...")